top of page

CTC Detection System

Background Information​

Our CTC detection system has very high sensitivity due to our proprietary anti-EpCAM antibody (EpAb3-5), which has the highest binding affinity in the world (Kd < 10^-12), as tested and published by Professor Leon Terstappen (https://www.decisivescience.com/leon), the inventor of the only US FDA approved  CTC IVD device (CellSearch). Our CTC detection system is current launched in the clinics and medical centers in Taiwan, China, Japan, and Europe.

​

Applications

For the detection of circulating tumor cells in cancer patients with carcinoma for treatment evaluation and post-treatment monitoring. Our CTC system can also be used for assessing the inflammation levels in healthy subjects for preventive healthcare.

​

Competitive Advantages

  • CTC capture rate  reaching  >95ï¼… (100 blood samples from patients with gastric, breast and colon cancers)

  • Captured CTC successful culture rate is 96%(out of 50 samples).

  • Our CTC Positive Selection Reagent has much higher sensitivity than other platforms and can capture cancer cells that other platforms can not (Can capture low EpCAM  expression cancer cell line, MDA-MB-231 )

​

Product Details

  • Product name:  Anti-EpCAM Monoclonal Antibody beads

  • Catalog number: BMI-EPCAMAb35-Beads

  • Size: 2ml

  • Gene: EpCAM

  • Purity: IgG purified

  • Isotype: IgG2b

  • Immunogen: Purified EpCAM

  • Localization: Cell membrane

  • Host: Mouse

  • Clone: EpAb3-5

  • Clonality: Monoclonal

  • Category: Primary

  • Target species: Human

  • Specificity:  This antibody has specificity for EpCAM

  • Species specificity: Cross-reacts with Human. Does not cross react with mouse

  • Dilution range: 20 reactions

  • Form:  Liquid (PBS (pH 7.4) with 0.09% NaN3)

  • Conjugate: protein G beads

  • Shipping and storage: 2-8°C, DO NOT FREEZE 

Pic 1.png
Pic 2.png

Product Information

​

References​

  1. Andree, Kiki C., et al. "Capture of tumor cells on anti-EpCAM-functionalized poly (acrylic acid)- coated surfaces." ACS applied materials & interfaces 8.23 (2016): 14349- 14356.

  2. Went, P.T., et al. “ Frequent EpCAM protein expression in human carcinomas.” Hum Pathol (2004): 35, 122-128. 

  3. Xu, H., et al.  “Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood.” Biomaterials (2011): 32, 9758-9765.

  4. Zborowski, M., and Chalmers, J.J. “Rare cell separation and analysis by magnetic sorting.” Anal Chem (2011): 83, 8050-8056.

  5. Imrich, S., Hachmeister, M., and Gires, O. “EpCAM and its potential role in tumor- initiating cells.” Cell Adh Migr(2012): 6, 30-38.

  6. Grover, P.K., et al. “Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research.” Ann Oncol (2014): 25, 1506-1516.

  7. Plouffe, B.D., Murthy, S.K., and Lewis, L.H. “ Fundamentals and application of magnetic particles in cell isolation and enrichment: a review.” Rep Prog Phys. (2015): 78, 016601.

  8. Raimondi, C., Nicolazzo, C., and Gradilone, A.” Circulating tumor cells isolation:  the "post-EpCAM era". Chin J Cancer Res(2015): 27, 461-470.

  9. Schneck, H., Gierke, B., et al.” EpCAM-Independent Enrichment of Circulating Tumor Cells in etastatic Breast Cancer. “PLoS One (2015): 10, e0144535

​​

Questions? Please write us
bottom of page